قالب وردپرس درنا توس
Home / Tips and Tricks / Vaccine for COVID-19 in 2020 is getting closer to reality: what we know about the best candidates today

Vaccine for COVID-19 in 2020 is getting closer to reality: what we know about the best candidates today


Experts are now hopeful that a vaccine for the SARS-CoV-2 virus will become available sooner rather than later.

SOPA Images / Getty Images

Visit the WHO website for the most current news and information about the coronavirus pandemic.

By the end of 2020, a COVID-19 vaccine is still not approved in the US. However, that may change in the coming weeks. There are two likely candidates who will most likely be the first to receive Food and Drug Administration approval and arrive for some people before 2021.

Not only that, but clinical studies have shown that two are about 95% effective in preventing COVID-19 infections. The claim means that more than nine in ten people who receive these vaccines are unlikely to receive COVID-19, even if they are exposed to SARS-CoV-2, the virus that causes the disease after being vaccinated.

US pharmaceutical giant Pfizer announced it has a vaccine that showed 95% efficacy in tests conducted on 43,538 people in six countries, with no serious safety concerns. Moderna, an American biotech company, announced last week that its vaccine has been demonstrated almost 95% effective and also relatively safe in a trial involving more than 30,000 people. Another vaccine under development by Oxford University and biotech company AstraZeneca is on average 70.4% effective, Oxford University announced this on Monday. Each vaccine requires a starting dose plus another “booster dose” a few weeks later.

Now playing:
Look at this:

Your phone may be a powerful tool to …


Moderna and Pfizer plan to apply for an emergency permit from the FDA this month. Pfizer expects, if authorized, to produce up to 50 million doses of vaccines by 2020 and 1.3 billion by 2021. Moderna plans to ship 20 million doses by 2020 and another 500 million to 1 billion by 2021, if permitted. With more than 330 million people in the US alone, not everyone will be able to receive a vaccine Immediately – the first doses to hit the market are likely to go to healthcare workers, followed by essential workers, those with underlying medical conditions, and older adults. Oxford’s next step is to submit the collected data to regulators around the world for product approval.

Pfizer, Moderna and Oxford are just the tip of the iceberg. Currently, there are 67 coronavirus vaccines in various stages of clinical trials, and a handful are almost ready to apply for authorization. Most experts think we’ll have even more ready to distribute in early 2021, but life may not start returning to normal until 2022.

Here we walk you through the top news about coronavirus vaccines and explain where the most promising candidates stand. This article is regularly updated and is intended as a general overview and not a source of medical advice. If you are looking for more information about coronavirus testing, here’s how to find a testing site near you.


An effective coronavirus vaccine may be the only way to end preventative measures such as social distancing and face masks.

James Martin / CNET

Important news about COVID-19 vaccines

The development of the COVID-19 vaccine is very fast

Several acceleration efforts are currently underway, such as the White House’s Operation Warp Speed, which aims to cut the red tape to accelerate vaccine development and be ready to distribute vaccines once they receive FDA approval. So far, the US government has pledged more than $ 10 billion to several vaccine manufacturers to secure a total of 800 million vaccine doses.


Experts say the recent spikes in coronavirus cases are not just the result of the US running more tests, as a higher percentage of those tested come out positive compared to earlier stages of the pandemic.

James Martin / CNET

Vaccines typically take about 10 to 15 years to develop and approve, through four stages, including human trials. But with Operation Warp Speed, approved vaccine projects can send data to the FDA little by little, instead of submitting all of the data from a four-phase trial at once.

Meanwhile, the program also supports financial efforts to begin manufacturing doses while clinical trials are ongoing. That means that if and when those vaccines are authorized, there will already be a supply of doses that can be distributed nationally.

Other promising coronavirus vaccines around the world

Here’s a quick look at some of the front runners alongside Pfizer and Moderna in the race to find a vaccine for COVID-19, including where the vaccines are developed, where they test them, and when scientists think they might be ready for widespread distribution, if known.

Now playing:
Look at this:

Vaccines, antibody tests, treatments: the science of …


Oxford University / AstraZeneca (UK): AstraZeneca began testing on 100,000 human volunteers in at least three countries. Lead investigator Dr. Sarah Gilbert had initially said AstraZeneca is aiming for a fall 2020 release and while that may be optimistic on this point after briefly pausing the process to investigate a participant’s illness, it does not appear to have slowed down significantly . It is currently 70% effective on average.

Sinovac (China): Currently, the vaccine is being tested on about 10,000 human volunteers in China and about 9,000 in Brazil, and will soon begin testing on about 1,900 subjects in Indonesia. Honesti Basyir, the president of Bio Farma, Sinovac’s Indonesian partner, has said he expects the vaccine to be ready in early 2021.

Sinopharm (China): Currently, around 15,000 volunteers in the Middle East are being tested in a trial that the state-owned company expects to take three to six months. Initial results suggest the drug is safe and at least somewhat effective. Sinopharm recently built a second facility to produce the vaccine, doubling its capacity to approximately 200 million doses per year.

CanSino Biologics (China): CanSino’s vaccine, which will begin large-scale human trials this summer, has already been approved by the Chinese military. The vaccine is based on a modified cold virus, which some experts warn could make it less effective than other vaccine efforts.


Wearing a face mask remains the surest way to prevent transmission of the coronavirus.

Robert Rodriguez / CNET

How many vaccines does the US need?

We probably won’t know until next year, but Fauci has suggested that we might need different vaccines created and distributed by different labs to end the pandemic, in an article published May 11 in the journal Science has been published. He has also said that he envisions different vaccines being given to different patient populations. For example, one vaccine for the elderly or other high-risk patients, another for healthy adults and another for children.

What if people don’t trust the vaccines?

Getting one or more vaccines through clinical trials to FDA approval is just the first part of the journey. The next thing is to convince people to take it. Sixty-three percent of American adults expressed concerns about the safety of a coronavirus vaccine, according to an Oct. 19 Harris Poll, with 40% of respondents specifically concerned that the development is to fast. Some people are reported to be concerned about possible side effects.

Life in the US will return to normal if we achieve what scientists call “herd immunity,” which, with regard to the coronavirus, means that at least 60% to 70% of the population is immune. As long as enough people are taking the vaccine to reach that level, it doesn’t matter if a few people object or refuse to take the vaccine for other reasons, such as if they are not healthy enough to be vaccinated.


Most experts expect a vaccine against the novel coronavirus, SARS-CoV-2, by 2021.

James Martin / CNET

What to do until a coronavirus vaccine is approved?

Coronaviruses are a large class of viruses and so far there are none of these vaccines. While early results are promising, there is no guarantee that a vaccine will be ready by 2021. Statistically, only about 6% of vaccine candidates ever make it to the market, according to an April Reuters report. However, health officials are very optimistic that the Pfizer vaccine and similar vaccines can end the coronavirus pandemic.

Whether COVID-19 vaccines are effective in stopping the spread of coronavirus depends a lot on how our bodies build immunity to the disease. Here’s what we know so far about whether or not you can do it get COVID-19 more than once. Testing is also key to slowing the spread of the coronavirus – learn more about a device that can yield results in less than 90 minutes here. Finally, read how all these issues and more weigh on US President-elect Joseph Biden’s plan to fight COVID-19.

The information in this article is for educational and informational purposes only and is not intended to be health or medical advice. Always consult a physician or other qualified health care practitioner if you have any questions about a medical condition or health goals.

Source link